NASDAQ:OPNT - Opiant Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $15.38 +0.13 (+0.85 %) (As of 12/18/2018 05:45 AM ET)Previous Close$15.25Today's Range$14.70 - $15.3852-Week Range$12.75 - $32.28Volume48,600 shsAverage Volume38,939 shsMarket Capitalization$58.48 millionP/E Ratio5.23Dividend YieldN/ABeta0.27 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine. Opiant Pharmaceuticals, Inc. has a collaboration agreement with Titan Pharmaceuticals, Inc. to explore development of a novel approach to the prevention of opioid relapse and overdose in individuals with opioid use disorder. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Santa Monica, California. Opiant Pharmaceuticals, Inc. is a subsidiary of Pelikin Group. Receive OPNT News and Ratings via Email Sign-up to receive the latest news and ratings for OPNT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Metal mining Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OPNT Previous Symbol CUSIPN/A Webwww.opiant.com Phone310-598-5410 Debt Debt-to-Equity RatioN/A Current Ratio7.87 Quick Ratio7.87 Price-To-Earnings Trailing P/E Ratio5.23 Forward P/E Ratio-3.35 P/E GrowthN/A Sales & Book Value Annual Sales$18.45 million Price / Sales3.19 Cash Flow$3.2109 per share Price / Cash Flow4.79 Book Value$0.02 per share Price / Book769.00 Profitability EPS (Most Recent Fiscal Year)$2.94 Net Income$6.58 million Net Margins-187.13% Return on Equity-175.03% Return on Assets-107.02% Miscellaneous Employees11 Outstanding Shares3,830,000Market Cap$58.48 million OptionableNot Optionable Opiant Pharmaceuticals (NASDAQ:OPNT) Frequently Asked Questions What is Opiant Pharmaceuticals' stock symbol? Opiant Pharmaceuticals trades on the NASDAQ under the ticker symbol "OPNT." How were Opiant Pharmaceuticals' earnings last quarter? Opiant Pharmaceuticals Inc (NASDAQ:OPNT) issued its quarterly earnings results on Wednesday, November, 7th. The technology company reported ($0.32) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by $0.21. The technology company earned $4.37 million during the quarter, compared to the consensus estimate of $4.70 million. Opiant Pharmaceuticals had a negative net margin of 187.13% and a negative return on equity of 175.03%. View Opiant Pharmaceuticals' Earnings History. What price target have analysts set for OPNT? 1 Wall Street analysts have issued 1-year price objectives for Opiant Pharmaceuticals' shares. Their forecasts range from $42.00 to $42.00. On average, they expect Opiant Pharmaceuticals' stock price to reach $42.00 in the next twelve months. This suggests a possible upside of 173.1% from the stock's current price. View Analyst Price Targets for Opiant Pharmaceuticals. What is the consensus analysts' recommendation for Opiant Pharmaceuticals? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opiant Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Opiant Pharmaceuticals. Has Opiant Pharmaceuticals been receiving favorable news coverage? Headlines about OPNT stock have been trending negative this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Opiant Pharmaceuticals earned a media sentiment score of -2.4 on InfoTrie's scale. They also gave headlines about the technology company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the stock's share price in the next few days. Who are some of Opiant Pharmaceuticals' key competitors? Some companies that are related to Opiant Pharmaceuticals include Fission Uranium (FCUUF), Amerigo Resources (ARREF), Rubicon Minerals (RBYCF), Jaguar Mining (JAGGF), Wealth Minerals (WMLLF), Alderon Iron Ore (AXXDF), Atlatsa Resources (ATLRF), Silver Bull Resources (SVBL), Santa Fe Gold (SFEG), US Gold (USAU), Quantum Materials (QTMM), Westwater Resources (WWR), Avalon Advanced Materials (AVLNF), Quaterra Resources (QTRRF) and Endurance Explorations Group (EXPL). Who are Opiant Pharmaceuticals' key executives? Opiant Pharmaceuticals' management team includes the folowing people: Dr. Roger Crystal, CEO & Director (Age 42)Mr. David D. O'Toole, Chief Financial Officer (Age 59)Mr. Kevin Andrew Pollack Esq., J.D., M.B.A., Advisor (Age 48)Dr. Phil Skolnick, Chief Scientific Officer (Age 71)Mr. Quan Vu, VP of Corp. Devel. Who are Opiant Pharmaceuticals' major shareholders? Opiant Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Stonepine Capital Management LLC (4.85%), Vanguard Group Inc (2.75%), Vanguard Group Inc. (2.75%), Granite Point Capital Management L.P. (1.96%) and Brasada Capital Management LP (0.50%). Company insiders that own Opiant Pharmaceuticals stock include Ann L Macdougall, David D O'toole, Geoffrey Wolf, Kevin Pollack, Michael Sinclair, Phil Skolnick, Roger Crystal and Thomas T Thomas. View Institutional Ownership Trends for Opiant Pharmaceuticals. Which institutional investors are buying Opiant Pharmaceuticals stock? OPNT stock was purchased by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Granite Point Capital Management L.P., Vanguard Group Inc, Vanguard Group Inc. and Brasada Capital Management LP. Company insiders that have bought Opiant Pharmaceuticals stock in the last two years include Ann L Macdougall, David D O'toole, Kevin Pollack, Michael Sinclair and Roger Crystal. View Insider Buying and Selling for Opiant Pharmaceuticals. How do I buy shares of Opiant Pharmaceuticals? Shares of OPNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Opiant Pharmaceuticals' stock price today? One share of OPNT stock can currently be purchased for approximately $15.38. How big of a company is Opiant Pharmaceuticals? Opiant Pharmaceuticals has a market capitalization of $58.48 million and generates $18.45 million in revenue each year. The technology company earns $6.58 million in net income (profit) each year or $2.94 on an earnings per share basis. Opiant Pharmaceuticals employs 11 workers across the globe. What is Opiant Pharmaceuticals' official website? The official website for Opiant Pharmaceuticals is http://www.opiant.com. How can I contact Opiant Pharmaceuticals? Opiant Pharmaceuticals' mailing address is 201 SANTA MONICA BOULEVARD SUITE 500, SANTA MONICA CA, 90401. The technology company can be reached via phone at 310-598-5410 or via email at [email protected] MarketBeat Community Rating for Opiant Pharmaceuticals (NASDAQ OPNT)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 184 (Vote Outperform)Underperform Votes: 191 (Vote Underperform)Total Votes: 375MarketBeat's community ratings are surveys of what our community members think about Opiant Pharmaceuticals and other stocks. Vote "Outperform" if you believe OPNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPNT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/18/2018 by MarketBeat.com StaffFeatured Article: How are institutional investors different from individual investors?